Welcome to our dedicated page for Cabaletta Bio SEC filings (Ticker: CABA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cabaletta Bio’s latest 10-K can read like an immunology textbook—dense tables on CARTA and CAART trial cohorts, layered milestone clauses, and pages of manufacturing risk factors. If you have ever searched “Cabaletta Bio SEC filings explained simply” or hunted for dosing data buried deep within, you know the challenge. Stock Titan turns those hundreds of pages into concise intelligence you can act on.
Our AI-powered summaries extract essentials from every Cabaletta Bio quarterly earnings report 10-Q filing, flagging R&D cash burn and RESET trial updates. Real-time alerts capture Cabaletta Bio insider trading Form 4 transactions the moment they hit EDGAR, so you never miss a Cabaletta Bio Form 4 insider transactions real-time disclosure. Need a Cabaletta Bio annual report 10-K simplified, a quick Cabaletta Bio earnings report filing analysis, or clarity on a sudden Cabaletta Bio 8-K material events explained? Ask the platform—understanding Cabaletta Bio SEC documents with AI becomes effortless.
- Pipeline progress – track clinical milestones straight from 8-K trial announcements.
- Capital strategy – examine collaboration revenue, at-the-market offerings, and cash runway inside each 10-Q.
- Insider sentiment – monitor Cabaletta Bio executive stock transactions Form 4 and Cabaletta Bio proxy statement executive compensation for context.
Every filing type—10-K, 10-Q, 8-K, S-1, and more—is updated in seconds, complete with expert commentary. Spend minutes, not weekends, staying ahead of Cabaletta Bio disclosures.
Alyeska entities and Anand Parekh report shared beneficial ownership of 8,904,367 shares of Cabaletta Bio common stock, representing 9.9% of the outstanding class. The reported position reflects 4,800,000 directly held shares plus warrants exercisable only to the extent permitted under their terms so that post-exercise ownership does not exceed 9.9% of the company's outstanding common stock. The filing notes the warrant cap limits actual exercisable shares to 4,104,367 under the agreement and that the percentage calculation uses the issuer's prospectus share count of 89,943,101. The reporting parties filed a joint statement and certify the holdings are in the ordinary course of business.
Cormorant Asset Management, LP and Bihua Chen reported beneficial ownership of 5,000,000 shares of Cabaletta Bio common stock, equal to 5.47% of the outstanding class. The filing attributes sole voting and dispositive power of these shares as 0 and shared voting and dispositive power as 5,000,000. The shares are held by the Cormorant Funds and the filing identifies Cormorant Global Healthcare Master Fund, LP as having rights to more than 5% of the referenced shares. The ownership percentage is calculated using 91,465,233 shares outstanding as reported as of August 1, 2025. The filers certify the shares were acquired and are held in the ordinary course of business and not for the purpose of changing control, and they submitted a joint filing statement accepting responsibility for their portions of the disclosure.
Adage Capital Management, L.P. and affiliated reporting persons disclose beneficial ownership of 9,002,580 shares of Cabaletta Bio common stock, representing 9.99% of the outstanding class. The reported total includes 172,822 shares issuable upon exercise of warrants held by Adage's affiliate and is calculated using 89,943,101 shares reported outstanding in the company's prospectus.
The filing identifies Robert Atchinson and Phillip Gross as reporting persons and lists Adage as investment manager for Adage Capital Partners with a business address at 200 Clarendon Street, Boston. The cover rows show 0 shares of sole voting or dispositive power and 9,002,580 shares of shared voting and dispositive power. The reporting persons certify the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.
In this Schedule 13G/A, Steven Nichtberger reports beneficial ownership of 3,034,499 shares of Cabaletta Bio common stock, representing approximately 3.3% of the outstanding class. The total comprises 986,483 shares held directly (about 1.1%), 363,000 shares held by the 2017 Nichtberger Family Trust (about 0.4%), and 1,685,016 shares underlying options exercisable within 60 days (about 1.8%).
The filing states Dr. Nichtberger has sole voting and dispositive power over all 3,034,499 shares. The reported percentages were calculated using 91,451,899 outstanding shares plus the exercisable options deemed outstanding under SEC rules. The filing indicates no shared voting power, no group affiliation, and no holdings reported on behalf of others.
Cabaletta Bio’s Q2-25 10-Q shows an enlarged pipeline but a materially higher cash burn. Operating expenses jumped 52% YoY to $45.9 M, driven by a 61% rise in R&D as the company advanced its CD19 CARTA program rese-cel across five autoimmune indications. The quarterly net loss widened to $45.1 M (-$0.73/sh) from $27.6 M (-$0.56/sh) one year ago; six-month loss reached $81.1 M.
Liquidity improved through an equity/warrant raise but a going-concern warning remains. In June the company issued 39.2 M shares plus 10.8 M pre-funded warrants, netting $93.6 M; an additional $2.6 M was raised via ATM sales. Cash & cash equivalents fell to $145.6 M but were supplemented by $49.1 M of new U.S. Treasury investments, lifting total cash & investments to $194.7 M. Lease-related assets boosted total assets to $224.5 M while finance lease liabilities rose to $20.3 M. Despite the capital infusion, management states that current resources “may not be sufficient” for 12 months, citing substantial doubt about going concern; cash burn from operations was $61.2 M in 1H-25.
Prudential Financial, Inc. (PFI) has filed Amendment No. 2 to Schedule 13G for Cabaletta Bio, Inc. (NASDAQ: CABA). As of 30 June 2025, PFI reports beneficial ownership of 10,391,167 common shares, representing 7.4 % of CABA’s outstanding stock. All shares are held with shared voting and dispositive power; PFI claims no sole authority over the shares.
The position is held through two investment-management subsidiaries: Jennison Associates LLC (10,107,167 shares; 7.2 %) and PGIM, Inc. (284,000 shares; 0.2 %). PFI classifies itself as a “parent holding company/ control person” under Rule 13d-1(b)(1)(ii)(G) and certifies the shares are held in the ordinary course of business, not to influence control of Cabaletta Bio.
Key takeaways for investors: 1) PFI remains a >5 % holder, indicating continued institutional support; 2) the stake size affords PFI meaningful, though not controlling, influence in shareholder matters; 3) no sale intention or activist purpose is disclosed.
FAQ
What is the current stock price of Cabaletta Bio (CABA)?
What is the market cap of Cabaletta Bio (CABA)?
